IRME IR-Med, Inc.

BEARISH Impact: 6/10 8-K
Horizon weeks Filed Jun 3, 2026 Processed 9d 13h ago SEC 0001493152-26-027047
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Latest settled — T+1d
IRME ▲ 0.00% at T+1d
SHORT call ✗ call lost 0.00% · α vs SPY -2.60% · entry $0.007000 → $0.007000
Next anchor: T+5d due 3d ago
Currently $0.007000 · -0.00% from $0.007000 entry (call sign-flipped)
Entry anchored
Jun 3, 2026
via day open
T+1d
0.00%
call 0.00% · α -2.60%
$0.007000
settled 9d ago
T+5d
call — · α —
due 3d ago
T+20d
call — · α —
in 19d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

IR-Med completed a private placement on May 31, 2026, raising $19,054 in gross proceeds through the sale of 250,000 shares at $0.10 per share and 250,000 warrants exercisable at $0.10 for five years. All purchasers were directors/chairman, signaling insider support. Separately, the board granted 11,056,507 fully vested options at $0.001 per share to three directors, creating massive potential dilution.

Key Financial Metrics

Offering Size
$19.1K

Actionable Insight

The combination of a tiny capital raise ($19K) and massive option grants (11M+ shares at $0.001) signals severe cash constraints and potential future dilution. Monitor for further capital raises or reverse splits. The insider participation is a modest positive signal but is overwhelmed by the dilution risk.

Key Facts

  • Private placement raised $19,054 from the sale of 250,000 shares at $0.10/share with 250,000 warrants at $0.10 exercise price.
  • All purchasers were directors/chairman (Oded Bashan, Yechiel Even, Ron Mayron, Aharon Klein, Yaniv Cohen, Ohad Bashan).
  • Board granted 5,040,000 options to Chairman Oded Bashan, 3,236,519 to Director Aharon Klein, and 2,779,988 to Director Yaniv Cohen — all fully vested at $0.001/share, 10-year term.
  • Options were granted outside the 2020 Incentive Stock Option Plan.
  • The offering closed on May 31, 2026; the 8-K was filed June 3, 2026.

Financial Impact

Gross proceeds of $19,054 from equity sale; potential dilution from 11,056,507 options at $0.001/share is massive relative to the 250,000 shares sold.

dilutionshare count

Risk Factors

  • Massive potential dilution from 11M+ options at near-zero exercise price.
  • Tiny capital raise suggests acute cash needs; further dilutive financing likely.
  • Options granted outside the 2020 plan may indicate governance concerns.

Market Snapshot

Exchange
OTC
Sector
Electromedical & Electrotherapeutic Apparatus

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-027047
Exhibit: ex4-1.htm0001493152-26-027047
Document: form8-k.htm0001493152-26-027047
Document: 0001493152-26-027047-index-headers.html0001493152-26-027047
Document: 0001493152-26-027047-index.html0001493152-26-027047
Document: 0001493152-26-027047.txt0001493152-26-027047

US Market Status

Market Closed — Opens Mon (52h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access